Merck to Hold Third-Quarter 2011 Sales and Earnings Conference Call on October 28

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2011 sales and earnings conference call with institutional investors and analysts at 8 a.m. EDT on Friday, Oct. 28. During the call, Kenneth C. Frazier, president and chief executive officer, Peter N. Kellogg, executive vice president and chief financial officer, and Adam H. Schechter, president, Global Human Health, will provide an overview of Merck’s financial performance for the quarter.

Investors, journalists and the general public may access a live audio webcast of the call on Merck’s website at http://www.merck.com/investors/events-and-presentations/home.html. Software needed to listen to the webcast is available on the corporate website and should be downloaded prior to the beginning of the webcast. A replay of the webcast will be available at approximately 11 a.m. EDT on Oct. 28 and will remain on the website for 12 months. The quarter's sales and earnings news release and supplemental financial disclosures also will be available in the Newsroom and Investor sections of the company's website at www.merck.com.

Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and use ID code number 11773565. Journalists who wish to ask questions are requested to contact a member of Merck's Media Relations team at the conclusion of the call.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.



CONTACT:

Merck
Media:
Steven Campanini, 908-423-4291
or
Investor:
Carol Ferguson, 908-423-4465

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.